INTRODUCTION {#sec1-1}
============

Development of the bioactive surgical additives is one of the great challenges of clinical research which has been used to regulate inflammation and increase the speed of healing process.\[[@ref1]\] A wide range of intra- and extraarticular events and various signaling proteins mediate and regulate the healing process of both hard and soft tissues, respectively. But understanding this entire process is still incomplete; however, it is known that platelets play a crucial role not only in hemostasis, but also in the wound healing process.\[[@ref2]\]

In 1974, platelets regenerative potentiality was introduced, and Ross *et al*.,\[[@ref3]\] were first to describe a growth factor from platelets. After activation of the platelets which are trapped within fibrin matrix, growth factors released and stimulate the mitogenic response in the bone periosteum during normal wound healing for repair of the bone.\[[@ref4]\] Better understanding of physiologic properties of platelets in wound healing since last two decades led to increase its therapeutic applications in the various forms showing varying results.

MATERIALS AND METHODS {#sec1-2}
=====================

Structured electronic search of scientific papers published up to 15^th^ March 2013 was carried out on the (<http://www.ncbi.nlm.nih.gov/pubmed>) entire PubMed database with a custom range of 5 years and hand search for term "platelet rich fibrin" (PRF); which was further filtered using Boolean operators (AND, OR, NOT) and combination of specific keywords as following: "Platelet rich fibrin Choukroun", "platelet rich fibrin in dentistry", "platelet rich fibrin dental", "platelet rich fibrin in maxillofacial surgery", "platelet rich fibrin implant", "platelet rich fibrin periodontal", "platelet rich fibrin extraction", and "platelet rich fibrin oral"; abstracts of all relevant papers were thoroughly scrutinized and in the end and articles pertaining to the topic (PRF) were included. Relevant literature for "platelet rich fibrin" in common dental textbooks and for additional information bibliographies of papers and review articles together with appropriate peer reviewed journals were also scrutinized. The inclusion criteria set for this review were: All case reports, case series, original research papers, review papers, *in vitro/in vivo* studies, animal studies, and controlled clinical trials on PRF used in dentistry related studies. Exclusion criteria consisted of studies that did not meet the above inclusion criteria.

The electronic search yielded 302 papers, out of which 72 were identified as suitable papers to the inclusion criteria and the remaining 230 were excluded \[[Figure 1](#F1){ref-type="fig"}\]. Only 75 papers selected, 72 from electronic search and three from other searches and full text of all articles retrieved and reviewed \[[Table 1](#T1){ref-type="table"}\], out of which 22 *in vivo* studies, 13 *in vitro* studies, 14 case reports, 11 animal studies, six controlled clinical trials, two combined *in vivo* and *in vitro* studies, and seven reviews \[[Figure 2](#F2){ref-type="fig"}\].
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PLATELET CONCENTRATE EVOLUTION {#sec1-3}
==============================

Platelets isolated from the peripheral blood acts as autologous source of growth factors. In general medical practice, platelet concentrate which is derived from blood can be used for the prevention and treatment of bleeding due to conditions like severe thrombocytopenia, severe oral hemorrhage associated with medullary aplasia, acute leukemia, etc.\[[@ref5]\] The use of fibrin adhesives helps to initiate the development of platelet concentrate as a bioactive surgical additive. Several components in blood has been recognized since 1990, which are a part of the natural healing process and have the potential to accelerate wound healing when added to wounded tissues or surgical sites. In 1970, fibrin glue formed by polymerizing fibrinogen with thrombin and calcium was first described. Actually, it was prepared using donor plasma; but the stability and quality of fibrin glue was low because of low concentration of fibrinogen in plasma. These fibrin adhesives can be derived autologously from the patient or can be obtained commercially, but with a small risk of disease transmission for the latter one.

PLATELET RICH PLASMA {#sec1-4}
====================

It has been shown in several studies that bone regenerative procedures may be enhanced by the addition of specific growth factors.\[[@ref6]\] platelet rich plasma (PRP) was used as a method of introducing concentrated growth factors platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor 1 (IGF-1) to the surgical site, thereby enriching the natural blood clot in order to hasten wound healing and stimulate bone regeneration.\[[@ref7]\] A natural human blood clot consists of 95% red blood cells (RBCs), 5% platelets, less than 1% white blood cells (WBCs), and numerous amounts of fibrin strands. A PRP blood clot, on the other hand, contains 4% RBCs, 95% platelets, and 1% WBCs.\[[@ref6]\] The PRP preparation protocol requires collection of blood with anticoagulant, centrifugation in two steps, and induced polymerization of the platelet concentrate using calcium chloride and bovine thrombin.\[[@ref8]\] PRP has been used in conjunction with different grafting materials in bone augmentation procedures since the day of its introduction; the results from these studies are controversial and no conclusions can be drawn regarding the bone regenerative effect of PRP till date.

PRF {#sec1-5}
===

PRF represents a new revolutionary step in the platelet gel therapeutic concept.\[[@ref1]\] Unlike other platelet concentrates, this technique does not require any gelifying agent, but not more than centrifugation of the natural blood without additives.\[[@ref8]\] Choukroun *et al*.,\[[@ref9]\] developed the PRF in 2001 at France and the production protocol of PRF attempts to accumulate platelets and released cytokines in a fibrin clot. Actually the platelets and leukocyte cytokines are important part in role play of this biomaterial, but the fibrin matrix supporting them is very helpful in constituting the determining elements responsible for real therapeutic potential of PRF.\[[@ref1]\] Cytokines are immediately used and destroyed in a healing wound. The harmony between cytokines and their supporting fibrin matrix has much more unique importance than any other constant. A fibrin glue, enriched with cytokines (such as PRP) with large uncontrollable and short-term effect is less better than a physiologic fibrin matrix (such as PRF) with good and better effects.

ADVANTAGES OF PRF OVER PRP {#sec1-6}
==========================

No biochemical handling of blood.\[[@ref15]\]

Simplified and cost-effective process.\[[@ref15]\]

Use of bovine thrombin and anticoagulants not required.\[[@ref15]\]

Favorable healing due to slow polymerization.\[[@ref15]\]

More efficient cell migration and proliferation.\[[@ref15]\]

PRF has supportive effect on immune system.\[[@ref15]\]

PRF helps in hemostasis.\[[@ref15]\]

PREPARATION OF PRF {#sec1-7}
==================

The protocol for PRF preparation is very simple and simulates that of PRP. It includes collection of whole venous blood (around 5 ml) in each of the two sterile vacutainer tubes (6 ml) without anticoagulant and the vacutainer tubes are then placed in a centrifugal machine \[[Figure 3](#F3){ref-type="fig"}\] at 3,000 revolutions per minute (rpm) for 10 min, after which it settles into the following three layers: Upper straw-colored acellular plasma, red-colored lower fraction containing red blood cells (RBCs), and the middle fraction containing the fibrin clot \[[Figure 4](#F4){ref-type="fig"}\]. The upper straw-colored layer is then removed and middle fraction is collected, 2 mm below to the lower dividing line, which is the PRF \[[Figure 5](#F5){ref-type="fig"}\]. The mechanism involved in this is; the fibrinogen concentrated in upper part of the tube, combines with circulating thrombin due to centrifugation to form fibrin. A fibrin clot is then formed in the middle between the red corpuscles at bottom and acellular plasma at the top. The middle part is platelets trapped massively in fibrin meshes. The success of this technique entirely depends on time gap between the blood collection and its transfer to the centrifuge and it should be done in less time. The blood sample without anticoagulant, starts to coagulate almost immediately upon contact with the glass, and it decreases the time of centrifugation to concentrate fibrinogen. Following proper protocol and quick handling is the only way to obtain a clinically usable PRF clot charged with serum and platelets. Resistant autologous fibrin membranes may be available by driving out the fluids trapped in fibrin matrix.

![Collection of blood, blood in vacutainer tube after centrifugation, and centrifuge machine](JCD-16-284-g004){#F3}
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CLINICAL APPLICATION {#sec1-8}
====================

Choukroun *et al*.,\[[@ref9]\] are well known for using autologous PRF protocol in oral and maxillofacial surgery to improve bone healing in implant dentistry.\[[@ref9]\] The most common encountered problems are lack of adequate bone and proximity to anatomic structures at the implantation site and recent advancements of PRF usage in surgical procedures can predictably combat such difficulties.

Choukroun *et al*.,\[[@ref11]\] attempted to evaluate the potential of PRF in combination with freeze-dried bone allograft (FDBA) in sinus floor elevation to enhance bone regeneration and nine sinus floor augmentations were performed. Out of nine; in six sites, FDBA with PRF (test group), and in three sites FDBA without PRF (control group) was used. After 4 months, the test group and for the control group after 8 months; bone specimens from the augmented region during the implant insertion procedure were harvested and evaluated. After 4 months of healing time, histologic maturation of the test group appears to be identical to that of the control group which was for a period of 8 months with equivalent quantities for both protocols.\[[@ref11]\]

In various bone reconstruction procedures Choukroun\'s PRF could provide a possible new bone. Mazor *et al*.,\[[@ref12]\] stated that use of PRF as the sole filling material during a simultaneous sinus lift and implantation procedure had stabilized a good amount of regenerated bone in the subsinus cavity up to the tip of implants in a case series through a radiological and histological evaluation at after 6 months from the surgery.\[[@ref12]\] Also they advocated that Choukroun\'s PRF, which is a simple and inexpensive biomaterial in systematic use during a sinus lift seems as an acceptable option.\[[@ref12]\]

Simonpieri *et al*.,\[[@ref13][@ref14]\] reported and confirmed the validate usage of PRF membranes in reconstruction protocols along with FDBA, 0.5% metronidazole solution in about 20 patients who were treated using this new technique and followed-up during 1-5 years, and finally 184 dental implants were placed and they found no implant or graft loss in a case series.\[[@ref13]\] PRF membranes protects the surgical site; promotes soft tissue healing; and when its fragments mixes with graft material, it functions as a "biological connector" between the different elements of graft and acts as a matrix which supports neoangiogenesis, capture of stem cells, and migration of osteoprogenitor cells to the center of graft.\[[@ref14]\]

PRF plugs can also be used in treating the residual extraction sockets.\[[@ref15]\] Use of autologous PRF in extracted socket filling after immediate bone augmentation using titanium membranes applied to the socket walls and primary closure was found to be feasible and safe with adequate bone filling after 8 weeks or above for implant fixation.\[[@ref16]\]

Anilkumar *et al*.,\[[@ref17]\] has reported PRF as a potential novel root coverage approach for treating gingival recession in mandibular anterior teeth using combined laterally positioned flap technique and PRF membrane.\[[@ref17]\] Combined use of PRF and bone graft with good results has also been reported for combined periodontic-endodontic furcation defect.\[[@ref18]\] Aroca *et al*.,\[[@ref19]\] in the 6 month of their randomized clinical trial, concluded that addition of a PRF membrane positioned under the MCAF (modified coronally advanced flap) provided inferior root coverage, but an additional gain in gingival/mucosal thickness (GTH) at 6 months compared to conventional therapy \[[Table 1](#T1){ref-type="table"}\].\[[@ref19]\]

DISCUSSION {#sec1-9}
==========

PRF first described by Choukroun *et al*.,\[[@ref9]\] is a new second generation of platelet concentrate. Simplified processing technique without any complex handling makes it superior to PRP. PRF can be used to promote wound healing, bone regeneration, graft stabilization, wound sealing, and hemostasis. Because the fibrin matrix is better organized, it is able to more efficiently direct stem cell migration and the healing program. Release of growth factors from PRF through *in vitro* studies and good results from *in vivo* studies led to optimize the clinical application of PRF. It was shown that there are better results of PRF over PRP. Dohan *et al*.,\[[@ref88]\] proved a slower release of growth factors from PRF than PRP and observed better healing properties with PRF. It was observed and shown that the cells are able to migrate from fibrin scaffold; while some authors demonstrated the PRF as a supportive matrix for bone morphogenetic protein as well.

CONCLUSION {#sec1-10}
==========

Although PRF belongs to a new generation of platelet concentrates, the biologic activity of fibrin molecule is enough in itself to account for significant cicatricial capacity of the PRF. The slow polymerization mode confers to PRF membrane as a particularly favorable physiologic architecture to support the healing process.

However, it is now necessary to look further into platelet and inflammatory features of this biomaterial. Only a perfect understanding of its components and their significance will enable us to comprehend the clinical results obtained and subsequently extend the fields of therapeutic application of this protocol.
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